Corporate social and environmental reporting: a review of the literature and a longitudinalstudy of UK disclosure

Article Abstract:

Studies of corporate social reporting literature have revealed that some effortsto classify it as either reactive or proactive are too simplistic. A re-examination of thehypothetical tensions that exists between the two extremes is presented, plus an overview ofpractical literature on social disclosure and some suggestions on how corporate social reportingresearch should progress.

Research, Social policy, Corporations, Disclosure statements (Accounting)

---

Do financial markets care about social and environmental disclosure?: further evidence and exploration from the UK

Article Abstract:

A study examining the relationship between performance of UK's largest companies on financial markets, and their social and environmental disclosures, is presented.

Public affairs, Securities issued, listed, Venture Analysis, Social aspects, Environmental aspects, Securities, Financial markets, Business enterprises, Company securities

---

Social, environmental and sustainability reporting and organizational value creation? Whose value? Whose creation?

Article Abstract:

A study conducted to examine the contribution of social, environmental and sustainability accounting in enhancing shareholders value is presented.

Personnel administration, Social Responsibility Accounting, Analysis, Compensation and benefits, Stockholders, Environmental auditing, Social accounting

Similar abstracts:

• Abstracts: Corporate cash holdings: and empirical investigation of UK companies. The number and the closeness of bank relationships
• Abstracts: Firm and environmental influences on the mode and sequence of foreign research and development activities
• Abstracts: Board characteristics, accounting report integrity, and the cost of debt. Founding-family ownership and firm performance: evidence from the S&P 500
• Abstracts: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
• Abstracts: Complementary therapies for inflammation. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.